404 related articles for article (PubMed ID: 34418521)
1. Polymeric and lipid nanoparticles for delivery of self-amplifying RNA vaccines.
Blakney AK; McKay PF; Hu K; Samnuan K; Jain N; Brown A; Thomas A; Rogers P; Polra K; Sallah H; Yeow J; Zhu Y; Stevens MM; Geall A; Shattock RJ
J Control Release; 2021 Oct; 338():201-210. PubMed ID: 34418521
[TBL] [Abstract][Full Text] [Related]
2. The role of nanoparticle format and route of administration on self-amplifying mRNA vaccine potency.
Anderluzzi G; Lou G; Woods S; Schmidt ST; Gallorini S; Brazzoli M; Johnson R; Roberts CW; O'Hagan DT; Baudner BC; Perrie Y
J Control Release; 2022 Feb; 342():388-399. PubMed ID: 34896446
[TBL] [Abstract][Full Text] [Related]
3. Big Is Beautiful: Enhanced saRNA Delivery and Immunogenicity by a Higher Molecular Weight, Bioreducible, Cationic Polymer.
Blakney AK; Zhu Y; McKay PF; Bouton CR; Yeow J; Tang J; Hu K; Samnuan K; Grigsby CL; Shattock RJ; Stevens MM
ACS Nano; 2020 May; 14(5):5711-5727. PubMed ID: 32267667
[TBL] [Abstract][Full Text] [Related]
4. Efficient
Opsomer L; Jana S; Mertens I; Cui X; Hoogenboom R; Sanders NN
J Mater Chem B; 2024 Apr; 12(16):3927-3946. PubMed ID: 38563779
[TBL] [Abstract][Full Text] [Related]
5. Formulation, inflammation, and RNA sensing impact the immunogenicity of self-amplifying RNA vaccines.
Tregoning JS; Stirling DC; Wang Z; Flight KE; Brown JC; Blakney AK; McKay PF; Cunliffe RF; Murugaiah V; Fox CB; Beattie M; Tam YK; Johansson C; Shattock RJ
Mol Ther Nucleic Acids; 2023 Mar; 31():29-42. PubMed ID: 36589712
[TBL] [Abstract][Full Text] [Related]
6. Inside out: optimization of lipid nanoparticle formulations for exterior complexation and in vivo delivery of saRNA.
Blakney AK; McKay PF; Yus BI; Aldon Y; Shattock RJ
Gene Ther; 2019 Sep; 26(9):363-372. PubMed ID: 31300730
[TBL] [Abstract][Full Text] [Related]
7. Polymer formulated self-amplifying RNA vaccine is partially protective against influenza virus infection in ferrets.
McKay PF; Zhou J; Frise R; Blakney AK; Bouton CR; Wang Z; Hu K; Samnuan K; Brown JC; Kugathasan R; Yeow J; Stevens MM; Barclay WS; Tregoning JS; Shattock RJ
Oxf Open Immunol; 2022; 3(1):iqac004. PubMed ID: 35996628
[TBL] [Abstract][Full Text] [Related]
8. From influenza to COVID-19: Lipid nanoparticle mRNA vaccines at the frontiers of infectious diseases.
Pilkington EH; Suys EJA; Trevaskis NL; Wheatley AK; Zukancic D; Algarni A; Al-Wassiti H; Davis TP; Pouton CW; Kent SJ; Truong NP
Acta Biomater; 2021 Sep; 131():16-40. PubMed ID: 34153512
[TBL] [Abstract][Full Text] [Related]
9. Production, Characterization, and Assessment of Permanently Cationic and Ionizable Lipid Nanoparticles for Use in the Delivery of Self-Amplifying RNA Vaccines.
Kairuz D; Samudh N; Ely A; Arbuthnot P; Bloom K
Pharmaceutics; 2023 Apr; 15(4):. PubMed ID: 37111658
[TBL] [Abstract][Full Text] [Related]
10. Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice.
McKay PF; Hu K; Blakney AK; Samnuan K; Brown JC; Penn R; Zhou J; Bouton CR; Rogers P; Polra K; Lin PJC; Barbosa C; Tam YK; Barclay WS; Shattock RJ
Nat Commun; 2020 Jul; 11(1):3523. PubMed ID: 32647131
[TBL] [Abstract][Full Text] [Related]
11. Lipid nanoparticle formulations for optimal RNA-based topical delivery to murine airways.
Tam A; Kulkarni J; An K; Li L; Dorscheid DR; Singhera GK; Bernatchez P; Reid G; Chan K; Witzigmann D; Cullis PR; Sin DD; Lim CJ
Eur J Pharm Sci; 2022 Sep; 176():106234. PubMed ID: 35688311
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial.
Pollock KM; Cheeseman HM; Szubert AJ; Libri V; Boffito M; Owen D; Bern H; O'Hara J; McFarlane LR; Lemm NM; McKay PF; Rampling T; Yim YTN; Milinkovic A; Kingsley C; Cole T; Fagerbrink S; Aban M; Tanaka M; Mehdipour S; Robbins A; Budd W; Faust SN; Hassanin H; Cosgrove CA; Winston A; Fidler S; Dunn DT; McCormack S; Shattock RJ;
EClinicalMedicine; 2022 Feb; 44():101262. PubMed ID: 35043093
[TBL] [Abstract][Full Text] [Related]
13. Delivery and Expression of mRNA in the Secondary Lymphoid Organs Drive Immune Responses to Lipid Nanoparticle-mRNA Vaccines after Intramuscular Injection.
Takanashi A; Pouton CW; Al-Wassiti H
Mol Pharm; 2023 Aug; 20(8):3876-3885. PubMed ID: 37491979
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of a self-amplifying mRNA reporter vaccine in explant models of broiler chickens.
Snoeck J; Chiers K; Tam Y; Sanders NN; Garmyn A
Poult Sci; 2023 Nov; 102(11):103078. PubMed ID: 37801866
[TBL] [Abstract][Full Text] [Related]
15. Design of SARS-CoV-2 hFc-Conjugated Receptor-Binding Domain mRNA Vaccine Delivered
Elia U; Ramishetti S; Rosenfeld R; Dammes N; Bar-Haim E; Naidu GS; Makdasi E; Yahalom-Ronen Y; Tamir H; Paran N; Cohen O; Peer D
ACS Nano; 2021 Jun; 15(6):9627-9637. PubMed ID: 33480671
[TBL] [Abstract][Full Text] [Related]
16. Modulating the immune response to SARS-CoV-2 by different nanocarriers delivering an mRNA expressing trimeric RBD of the spike protein: COVARNA Consortium.
Marcos-Villar L; Perdiguero B; Anthiya S; Borrajo ML; Lou G; Franceschini L; Esteban I; Sánchez-Cordón PJ; Zamora C; Sorzano CÓS; Jordá L; Codó L; Gelpí JL; Sisteré-Oró M; Meyerhans A; Thielemans K; Martínez-Jiménez F; López-Bigas N; García F; Alonso MJ; Plana M; Esteban M; Gómez CE
NPJ Vaccines; 2024 Mar; 9(1):53. PubMed ID: 38448450
[TBL] [Abstract][Full Text] [Related]
17. Optimization of Lipid Nanoparticles for saRNA Expression and Cellular Activation Using a Design-of-Experiment Approach.
Ly HH; Daniel S; Soriano SKV; Kis Z; Blakney AK
Mol Pharm; 2022 Jun; 19(6):1892-1905. PubMed ID: 35604765
[TBL] [Abstract][Full Text] [Related]
18. OX40 agonist stimulation increases and sustains humoral and cell-mediated responses to SARS-CoV-2 protein and saRNA vaccines.
Duhen R; Beymer M; Jensen SM; Abbina S; Abraham S; Jain N; Thomas A; Geall AJ; Hu HM; Fox BA; Weinberg AD
Front Immunol; 2022; 13():896310. PubMed ID: 36238275
[TBL] [Abstract][Full Text] [Related]
19. Chemistry of Lipid Nanoparticles for RNA Delivery.
Eygeris Y; Gupta M; Kim J; Sahay G
Acc Chem Res; 2022 Jan; 55(1):2-12. PubMed ID: 34850635
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant lipidoid-substituted lipid nanoparticles augment the immunogenicity of SARS-CoV-2 mRNA vaccines.
Han X; Alameh MG; Butowska K; Knox JJ; Lundgreen K; Ghattas M; Gong N; Xue L; Xu Y; Lavertu M; Bates P; Xu J; Nie G; Zhong Y; Weissman D; Mitchell MJ
Nat Nanotechnol; 2023 Sep; 18(9):1105-1114. PubMed ID: 37365276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
